1,1-dimethylethyl N-(4-thioureidophenylmethyl)carbamate | 319496-44-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-dimethylethyl N-(4-thioureidophenylmethyl)carbamate
• 英文别名: (4-thioureido-benzyl)-carbamic acid tert-butyl ester；tert-butyl N-[[4-(carbamothioylamino)phenyl]methyl]carbamate
• CAS: 319496-44-1
• 化学式: C₁₃H₁₉N₃O₂S
• 分子量: 281.379
• InChiKey: ZNJABOVEROEXKR-UHFFFAOYSA-N

物化性质

• 熔点：
  89-91 °C
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Bromo-3-hydroxy-1-o-tolyl-propenone 、 1,1-dimethylethyl N-(4-thioureidophenylmethyl)carbamate 在 盐酸 作用下， 以 丙酮 、 1,4-二氧六环 为溶剂， 反应 32.0h， 以62%的产率得到[2-(3-aminomethyl-phenylamino)-thiazol-5-yl]-o-tolyl-methanone hydrochloride
  参考文献：
  名称：

  Thiazole derivatives

  摘要：

  提供了式I的噻唑衍生物，以及其药用盐和酯，其中R1至R5，a和b的含义如规范中所述。这些化合物是神经肽Y Y5受体拮抗剂，可用于治疗肥胖。

  公开号：

  US20050038089A1
• 作为产物：
  描述：

  4-硝基苄胺 在 氨 、 三乙胺 、 calcium carbonate 、 tin(ll) chloride 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 38.5h， 生成 1,1-dimethylethyl N-(4-thioureidophenylmethyl)carbamate
  参考文献：
  名称：

  Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase

  摘要：

  Inhibition of the isoforms of nitric oxide synthase (NOS) has important applications in therapy of several diseases, including cancer. Using 1400W [N-(3-aminomethylbenzyl)acetamidme], thiocitrulline and N-delta-(4,5-dihydrothiazol-2-yl)ornithine as lead compounds, series of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas were designed as inhibitors of NOS. Ring-substituted benzyl and phenyl isothiocyanates were synthesised by condensation of the corresponding amines with thiophosgene and addition of ammonia gave the corresponding thioureas in high yields. The substituted 2-amino-4,5-dihydrothiazoles were approached by two routes. Treatment of simple benzylamines with 2-methylthio-4,5-dihydrothiazole at 180degreesC afforded the corresponding 2-benzylamino-4,5-dihydrothiazoles. For less nucleophilic amines and those carrying more thermally labile substituents, the 4,5-dihydrothiazoles were approached by acid-catalysed cyclisation of N-(2-hydroxyethyl)thioureas. This cyclisation was shown to proceed by an S(N)2-like process. Modest inhibitory activity was shown by most of the thioureas and 4,5-dihydrothiazoles, with N-(3-aminomethylphenyl)thiourea (IC50 = 13 muM vs rat neuronal NOS and IC50 = 23 muM vs rat inducible NOS) and 2-(3-aminomethylphenylamino)-4,5-dihydrothiazole (IC50 - 13 muM vs rat neuronal NOS and IC50 = 19 muM vs human inducible NOS) being the most potent. Several thioureas and 4,5-dihydrothiazoles were found to stimulate the activity of human inducible NOS in a time-dependent manner. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00451-6

文献信息

• Selective NPY (Y5) antagonists
  申请人：Marzabadi R. Mohammad

  公开号：US20050137240A1

  公开（公告）日：2005-06-23

  This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

  本发明涉及选择性拮抗NPY（Y5）受体的双环和三环化合物。本发明提供一种制药组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组合而成的制药组合物。本发明还提供了制备制药组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。本发明进一步提供了使用本发明化合物制备用于治疗异常状态的制药组合物，其中减少人类Y5受体活性可缓解该异常状态。
• Selective NPY (Y5) antagonists (tricyclics)
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06225330B1

  公开（公告）日：2001-05-01

  This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  本发明涉及三环化合物，它们是选择性NPY（Y5）受体拮抗剂。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药用可接受载体。本发明提供了一种由本发明化合物的治疗有效量和药用可接受载体组合而成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药用可接受载体组合。
• SELECTIVE NPY (Y5) ANTAGONISTS
  申请人：H. LUNDBECK A/S

  公开号：EP1194421B1

  公开（公告）日：2005-10-12
• EP1194421A4
  申请人：——

  公开号：EP1194421A4

  公开（公告）日：2002-09-11
• 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1658288A1

  公开（公告）日：2006-05-24